CD57 is a sugar-based molecule found on the surface of certain immune cells, primarily natural killer (NK) cells and T cells, that flags them as having reached a late stage of maturation. It is one of the markers immunologists use to profile how “experienced” or “worn” a person’s immune system is. CD57 levels show up in clinical and research settings as a window into immune aging, chronic infections, and even cancer prognosis, but the marker is more nuanced than many popular health sources suggest.
The Molecule Itself
CD57 is a carbohydrate structure, not a protein. Its chemical identity is a sugar chain known as the HNK-1 epitope (short for Human Natural Killer-1), which gets attached to the surface of cells. You might also see it referred to as LEU-7 or L2 in older literature. Unlike many immune markers that are proteins encoded by a single gene, CD57 is a sugar tag added to existing proteins and lipids by specific enzymes. That distinction matters because the molecule does not work like a typical receptor that sends signals into the cell. Instead, CD57 acts more like a badge that tells researchers something about the cell’s history and state.
CD57 is not exclusive to immune cells. The same HNK-1 sugar epitope appears on nerve cells during embryonic development, where it plays a role in how neural crest cells migrate and how the connections between neurons mature. In developing hippocampal neurons, loss of the HNK-1 epitope led to fewer mature dendritic spines and disrupted the placement of key signaling proteins at synapses, suggesting it helps wire the brain correctly during early life.1Neuroscience. HNK-1 (human natural killer-1) glyco-epitope is essential for normal spine morphogenesis in developing hippocampal neurons In rat embryos, it was found specifically on migrating neural crest cells in the trunk, where it appeared to influence how far those cells traveled.2PubMed Central. Roles of HNK-1 carbohydrate epitope and its synthetic glucuronyltransferase genes on migration of rat neural crest cells These neural roles are mostly relevant during fetal development and are not what clinicians are measuring when they order a CD57 panel on an adult patient. But they do explain why the molecule pops up in unexpected contexts.
What CD57 Means on Natural Killer Cells
Natural killer cells go through a maturation process in the body, moving from relatively immature forms to highly experienced, potent killers. CD57 marks what appears to be the final stage of that journey. NK cells that carry CD57 on their surface are better at killing target cells directly, respond more strongly when triggered through certain activating receptors, and are less dependent on cytokine signals from other immune cells to do their work.3Frontiers in Immunology. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease The trade-off is that these fully mature NK cells have largely lost the ability to multiply. They are specialists, not generalists.
Researchers have mapped the NK cell maturation path as a one-way street: cells move from a CD56-bright stage (good at producing chemical signals but modest killers) through a CD56-dim/CD57-negative stage, and finally arrive at a CD56-dim/CD57-positive state that represents peak cytotoxic ability with minimal proliferative capacity.4PubMed Central. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset Newborns and fetuses have virtually no CD57-positive NK cells, which is consistent with the idea that these cells accumulate through a lifetime of immune challenges rather than being produced ready-made.3Frontiers in Immunology. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease
So when a blood test shows a high percentage of CD57-positive NK cells, it generally indicates a mature, experienced NK cell compartment. That is not inherently bad. These cells are potent defenders. But it does suggest the immune system has been through significant activation over time.
What CD57 Means on T Cells
On T cells, the picture is a bit different. CD57 has long been called a marker of “senescence,” meaning the cells wearing it are seen as old, exhausted, and unable to divide. There is truth to that framing, but recent work shows it is an oversimplification. CD57-positive T cells do tend to have shorter telomeres and a reduced ability to proliferate compared to their CD57-negative counterparts.5Blood. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+T cells However, a 2025 review re-evaluating the evidence concluded that CD57 is not a definitive marker of senescence in the strict biological sense. Many CD57-positive T cells can still proliferate when properly activated, and some are found in early-differentiated compartments rather than exclusively at the end of the line.6PubMed Central. Re-evaluating CD57 as a marker of T cell senescence: implications for immune ageing and differentiation
The more accurate way to think about CD57 on T cells is as a record of prior immune activation. A T cell that has divided many times in response to infections or chronic inflammation is more likely to pick up CD57. The marker reflects history and declining proliferative reserve rather than a complete shutdown of function. This distinction matters clinically because labeling a cell “senescent” implies it is useless, when in reality CD57-positive T cells can still contribute to immune responses, just not by rapidly multiplying.
CD57 and Aging
One of the most consistent findings about CD57 is that it increases with age. Older adults carry substantially higher proportions of CD57-positive cells than younger people. In a study comparing CD8-positive T cells from young and old subjects, the CD28-negative/CD57-positive population, often considered the hallmark of immune aging, was about six times larger in older adults (roughly 35% vs 6%).7Archives of Gerontology and Geriatrics. Aging-associated subpopulations of human CD8+ T-lymphocytes identified by their CD28 and CD57 phenotypes Interestingly, the researchers also found a small CD28-positive/CD57-positive population that was more prevalent in older subjects, suggesting that CD57 accumulation with age occurs regardless of other surface markers typically associated with T cell exhaustion.
This age-related increase is why CD57 levels, in isolation, tell you relatively little without context. A 70-year-old with elevated CD57-positive T cells may simply have a normally aged immune system. It becomes more informative when levels are unexpectedly high for a person’s age, or when tracked over time in the context of a specific condition.
Chronic Infections Drive CD57 Up
Chronic viral infections are among the strongest drivers of CD57 expression, and cytomegalovirus (CMV) stands out as the most studied example. CMV is extremely common, infecting roughly half of adults in many populations, and usually causes no symptoms in healthy people. But the virus is never fully eliminated from the body. The immune system must keep it in check indefinitely, and that sustained pressure reshapes the NK cell and T cell landscape. During active CMV infection, a specific subset of NK cells that co-express CD57 and an activating receptor called NKG2C expands preferentially. Researchers have proposed that these CD57-positive/NKG2C-high NK cells may represent a form of immune memory, analogous to how T cells “remember” past infections.8PubMed Central. Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
HIV is another chronic infection where CD57 levels carry clinical weight. People living with HIV, even those on effective antiretroviral therapy, tend to have higher proportions of CD57-positive T cells than HIV-negative individuals. In one study, the group with the poorest immune recovery on treatment (immune non-responders) had especially high percentages of CD57-positive cells: about 39% of CD8 T cells and 44% of CD4 T cells carried CD57, compared with roughly 23% and 28% in those who responded well to treatment.9PubMed. CD57 T cells associated with immunosenescence in adults living with HIV or AIDS Elevated markers of both exhaustion and senescence, including CD57, were also observed in the T cells of HIV-positive participants compared to controls in a separate analysis.10PubMed Central. Markers of T Cell Exhaustion and Senescence and Their Relationship to Plasma TGF-β Levels in Treated HIV+ Immune Non-responders The elevated CD57 levels in HIV likely reflect the chronic immune activation and inflammation that persists even when the virus is well controlled by medication.
The Lyme Disease Controversy
If you have looked into CD57 testing before reading this article, there is a good chance it was in the context of Lyme disease. Some practitioners in the alternative and integrative medicine space use low CD57-positive NK cell counts as a marker of chronic Lyme infection, with the idea that the Borrelia bacterium suppresses this cell population. This practice became popular based on early, small studies and has persisted in certain clinical circles.
The evidence behind this claim is weak. A controlled study that compared people with post-Lyme disease syndrome, people who had recovered from Lyme, and healthy volunteers found no significant difference in NK cell counts between the groups.11PubMed Central. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls This is a small study, which limits what you can conclude from it in either direction, but it is notable that the straightforward hypothesis of “Lyme suppresses NK cells including CD57-positive ones” did not hold up when tested with proper controls. Major infectious disease guidelines do not recommend CD57 testing for diagnosing or monitoring Lyme disease. If a practitioner orders this test specifically to assess Lyme, it is worth asking what evidence they are relying on, because the mainstream immunology literature does not support the practice.
Chronic Fatigue Syndrome and CD57
CD57 has also been investigated in chronic fatigue syndrome (CFS), though the findings run in a direction some readers might not expect. Rather than being elevated, CD57 expression on T cells was significantly lower in CFS patients compared to healthy controls. Both the percentage of T cells carrying CD57 and the amount of CD57 per cell were reduced, with the per-cell reduction being especially pronounced.12PubMed. Decreased Expression of the CD57 Molecule in T Lymphocytes of Patients with Chronic Fatigue Syndrome This is a single study and should not be over-interpreted, but it hints that the relationship between CD57 and chronic illness is not simply “more CD57 = worse.” The direction of change depends on the condition and the type of immune cell being measured.
This finding also illustrates why CD57 testing is not a reliable stand-alone diagnostic tool for any single condition. The same marker can go up in one disease and down in another, and the meaning shifts depending on whether you are measuring NK cells or T cells, total counts or percentages.
Autoimmune Disease
In autoimmune conditions, CD57-positive T cells sometimes accumulate at sites of inflammation. Patients with rheumatoid arthritis (RA) had elevated levels of CD57-positive T cells not only in their blood but especially in joint fluid and the bone marrow adjacent to affected knee joints.13PubMed Central. Increase of CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis patients: implication for an anti-inflammatory role The researchers suggested these cells might actually play an anti-inflammatory role, which complicates the common assumption that CD57-positive cells are simply a sign of immune dysfunction. It is possible that CD57-positive T cells are being recruited to inflamed tissues as part of a regulatory feedback loop, though this interpretation remains debated.
CD57 and Cancer Prognosis
Perhaps the most clinically promising use of CD57 is as a prognostic marker in solid tumors. When pathologists examine tumor tissue and count how many CD57-positive immune cells have infiltrated the tumor, higher counts consistently predict better survival. A meta-analysis pooling data from 27 studies and nearly 4,400 patients found that higher CD57-positive cell infiltration was associated with roughly halved risk of death, and this association held up when restricted to studies that used multivariate analysis to control for other factors.14Frontiers in Immunology. Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis A separate meta-analysis similarly found that CD57-positive lymphocyte infiltration improved one-year, three-year, and five-year survival across multiple cancer types.15PubMed Central. Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: a meta-analysis
In colorectal cancer specifically, CD57-positive cell density within the tumor independently predicted both recurrence-free and overall survival after adjusting for tumor stage, grade, and whether the patient received chemotherapy.16British Journal of Cancer. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer This makes intuitive sense given that CD57-positive NK cells are the most cytotoxic subset; if they manage to get into the tumor in large numbers, they are more likely to kill cancer cells effectively.
The melanoma story adds an interesting wrinkle. Researchers found that CD57-positive NK cells were about three and a half times more abundant in lymph nodes that contained tumor compared with tumor-free lymph nodes, and these cells co-expressed markers of activation and maturation.17Nature Communications. Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients The tumor-infiltrated lymph nodes appeared to be a site where NK cells preferentially gather and mature, suggesting the body actively directs its most potent killers toward the threat. This work has implications for immunotherapy research, since understanding which NK cell subsets are already present in tumors could help design better cell-based treatments.
Exercise and CD57-Positive Cells
Physical activity has a rapid and measurable effect on CD57-positive cell counts in the blood. In cancer patients undergoing chemotherapy, a single session of moderate-intensity continuous exercise caused an immediate spike in circulating NK cells, and the CD57-positive subset was among the most responsive to the exercise stimulus. Counts rose right after the workout and returned to baseline within an hour of stopping.18Brain, Behavior, & Immunity – Health. Acute natural killer cells response to a continuous moderate intensity and a work-matched high intensity interval exercise session in metastatic cancer patients treated with chemotherapy This transient mobilization is thought to be part of the body’s stress response, temporarily flooding the bloodstream with its most potent immune cells. It also means that CD57 NK cell counts can fluctuate substantially based on when the blood sample is drawn relative to physical activity, which is another reason to be cautious about reading too much into a single snapshot.
Why a Single CD57 Test Rarely Tells You Much
Given everything above, you can see why CD57 is a genuinely informative marker in the right context but a poor standalone diagnostic. The same person’s CD57 levels shift with age, recent exercise, time of day, concurrent infections, and the specific immune cell population being measured. A high CD57 count on NK cells could mean a mature, battle-ready immune system. A high CD57 count on T cells could reflect chronic viral infection, normal aging, or autoimmune inflammation. A low CD57 count could mean youth and immune naivety, or it could be associated with chronic fatigue syndrome.
The value of CD57 testing lies in pattern recognition within a broader immune panel, not as a number to interpret in isolation. In oncology, pathologists count CD57-positive cells within tumor tissue to help predict prognosis. In HIV medicine, CD57 levels help gauge immune aging alongside other markers. In research settings, CD57 distinguishes functionally distinct cell populations in ways that matter for designing immunotherapies. But when a wellness practitioner orders a CD57 NK cell count and uses a single number to diagnose or monitor a condition like Lyme disease, they are using the marker well outside the range of what the evidence supports.
CD57 Beyond Routine Immunology
The HNK-1 epitope that defines CD57 has a surprisingly broad biological footprint outside the immune system. As noted earlier, it shows up during embryonic brain development, but its neural roles extend further than just cell migration. In the hippocampus, the brain region critical for learning and memory, the HNK-1 epitope helps dendritic spines mature into their characteristic mushroom shape. Without it, spines stay immature and filopodium-like, and key signaling proteins that should concentrate at spine heads instead scatter along the dendrite shaft.1Neuroscience. HNK-1 (human natural killer-1) glyco-epitope is essential for normal spine morphogenesis in developing hippocampal neurons This means the same sugar molecule that immunologists track on blood cells also plays a structural role in how neurons form the connections that underlie memory.
This dual identity is unusual. Most immune markers are proteins that evolved for immune-specific functions. CD57’s carbohydrate nature allows it to be added to many different proteins across different tissues, giving it roles that seem unrelated until you remember that the molecule itself is just a sugar tag. The enzymes that attach it are expressed in both the immune system and the nervous system, which is why it keeps appearing in two very different research communities that rarely overlap. For the average patient getting a CD57 blood test, the neural biology is largely irrelevant. But it does mean that if you go searching for CD57 in the scientific literature, you will stumble into neurodevelopment papers alongside immunology ones, and now you know why.